Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer

Grants

Funding Acknowledgements

This study was financially supported by grants from the Department of Health and Human Services through the National Health and Medical Research Council of Australia (NHMRC, nos. APP1124309 to E.L.C., APP1161198 to D.D.L.B. and E.L.C., APP1117044 to D.D.L.B., APP1092856 to D.D.L.B., APP1186505 to D.W.G. and APP1189939 to N.L.B.), the US National Cancer Institute U54 program (no. U54CA209978 to A.B., J.T.C. and D.D.L.B.), Victorian Cancer Agency (no. ECSG15012 to E.L.C.), Tour de Cure (no. RSP-274-18/19 to E.L.C.) and Goldman Sachs Gives through the Peter MacCallum Cancer Foundation and Cancer Australia (no. APP1004673 to D.D.L.B.). Part of this study was supported by the US Department of Defense - Uniformed Services University of the Health Sciences (nos. HU0001-16-2-0006 and HU0001-16-2-0014 to G.L.M.). We gratefully acknowledge additional support from M. Rose and the Rose family, The WeirAnderson Foundation, Border Ovarian Cancer Awareness Group, donors to the Garvan Institute of Medical Research's Ovarian Cancer Research Program, W. Taylor and A. Coombs and family. The CASCADE study was supported by the Peter MacCallum Cancer Centre Foundation, and in kind by the Victorian Institute of Forensic Medicine and Tobin Brothers Funerals. The CASCADE investigators thank the CASCADE Management Committee, all staff at the Victorian Institute of Forensic Medicine, D. Stevens and Tobin Brothers Funerals. We acknowledge and thank the women and their families who generously participated in the CASCADE program making this work possible. We acknowledge the vital role of the Australian Ovarian Cancer Study (AOCS) in this study. AOCS was supported by the US Army Medical Research and Materiel Command (no. DAMD17-01-1-0729 to D.D.L.B.), The Cancer Council Victoria, Queensland Cancer Fund, The Cancer Council New South Wales, The Cancer Council South Australia, The Cancer Foundation of Western Australia and The Cancer Council Tasmania and NHMRC (nos. ID400413 and ID400281 to D.D.L.B.). AOCS acknowledges additional support from Ovarian Cancer Australia and the Peter MacCallum Cancer Centre Foundation. AOCS gratefully acknowledges the cooperation of the participating institutions in Australia, and acknowledges the contribution of the study nurses, research assistants and all clinical and scientific collaborators, in particular L. Bowes, D. Ariyaratne and N. Traficante. We thank E. Niedermayr, S. Guo, all the kConFab research nurses and staff, the heads and staff of the Family Cancer Clinics and the Clinical Follow Up Study (which has received funding from NHMRC, the National Breast Cancer Foundation, Cancer Australia and the National Institute of Health (USA)) for their contributions to this resource, and the many families who contribute to kConFab. We thank Peter MacCallum Cancer Centre Molecular Genomics core facility, supported by the Australian Cancer Research Foundation, and the Peter MacCallum Cancer Centre Bioinformatics core facility, in particular M. Jayawardana, for statistical advice. The WHIRC team acknowledge contributions by P. Akowuah, J. Loffredo, U. Rao, S. Makohon-Moore, J. Oliver, D. Mitchell and G. Gist. We thank the BC Cancer Foundation, Genome BC, Canadian Institutes for Health Research, Canadian Cancer Society, Terry Fox Research Institute and Canada Foundation for Innovation. Disclaimer: the views expressed herein are those of the authors and do not reflect the official policy of the Department of Army/Navy/Air Force, Department of Defense or US Government.